Chugai Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Chugai Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Chugai Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Chugai Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of F. Hoffmann-La Roche Ltd, develops biopharmaceuticals and therapeutic antibodies for the treatment of cancer, bone and joint diseases, renal diseases, autoimmune diseases, neurological and other diseases. The company’s focused R&D activities, proprietary technology platforms, and strategic alliance with Roche are its major strengths, even as overdependence on Japan and vulnerability to patent expirations could be the major cause of concern for the company. Chugai could benefit from regulatory approvals, contracts and agreements, and growing market for cancer treatments. However, failure to comply with government regulations, influx of generics, and increasing competition could affect the company’s performance.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer